Induction of lymphokine-activated killer cells against human leukemia cells in vitro
- 1 July 1989
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 59 (1) , 21-24
- https://doi.org/10.1007/bf00320242
Abstract
The induction of lymphokine-activated killer (LAK) cells against fresh human leukemia cells was investigated. Two thirds of the 62 leukemias examined were susceptible to the lytic effect of allogeneic IL-2 induced LAK cells in vitro. No substantial differences could be detected between myeloid or lymphoid leukemias or with regard to the FAB subtype or the immunophenotype. Culturing mononuclear cells from peripheral blood or bonemarrow of leukemia patients with IL-2 resulted in an expansion of residual large granular lymphocytes and development of cytotoxic activity. The combination of IL-2 with IFN-gamma or the presence of tumor cells during the activation process led to an enhancement of LAK cell cytotoxicity. These results suggest that LAK cells may be useful in the treatment of leukemia.Keywords
This publication has 19 references indexed in Scilit:
- INTERLEUKIN-2 INDUCTION OF LYMPHOKINE-ACTIVATED KILLER (LAK) ACTIVITY IN THE PERIPHERAL-BLOOD AND BONE-MARROW OF ACUTE-LEUKEMIA PATIENTS .1. FEASIBILITY OF LAK GENERATION IN ADULT PATIENTS WITH ACTIVE DISEASE AND IN REMISSION1988
- INTERLEUKIN-2 EXPANDED TUMOR-INFILTRATING LYMPHOCYTES IN HUMAN RENAL-CELL CANCER - ISOLATION, CHARACTERIZATION, AND ANTITUMOR-ACTIVITY1988
- PREFERENTIAL PROLIFERATION OF NATURAL-KILLER-CELLS AMONG PERIPHERAL-BLOOD MONONUCLEAR-CELLS COCULTURED WITH B-LYMPHOBLASTOID CELL-LINES1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- CYTOTOXICITY OF INTERLEUKIN-2-ACTIVATED LYMPHOCYTES FOR LEUKEMIA AND LYMPHOMA-CELLS1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562.The Journal of Experimental Medicine, 1985
- Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).The Journal of Immunology, 1985
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982